NovaBridge Biosciences (NBP) SEC Filings

NovaBridge Biosciences (NBP) reported the initial beneficial ownership status of director Dewhurst Martin William on a Form 3. The filing lists him as a director only and shows no reportable holdings or transactions in NovaBridge Biosciences equity securities at the time of this report.

NovaBridge Biosciences (NBP) received a notice under Rule 144 that Chief Business Development Officer Cao Sean Wuxiong plans to sell 46,947 Ordinary Shares through Citigroup Global Markets on or about September 9, 2026 on NASDAQ, with an aggregate market value of $79,377.99 and 265,377,891 shares outstanding.

The shares derive from restricted stock units vesting on September 3, 2026, when 147,554 shares were acquired as compensation, and the filing states that shares are being sold to cover obligations arising from the vesting and settlement of equity awards.

NovaBridge Biosciences (NBP) reports that Chief Business Development Officer Cao Sean Wuxiong exercised previously granted restricted share units on September 3, 2026, converting 147,553 RSUs into 339,372 Ordinary Shares represented by American Depositary Shares. These RSUs come from grants of 408,933 units in 2025 and 181,280 units in 2026 that vest over four years. No trades are reported under a Rule 10b5-1 trading plan.

NovaBridge Biosciences (NBP) reports the voting results of its 2026 annual general meeting of shareholders held on September 8, 2026 in Shanghai. Holders of 121,294,288 shares, representing approximately 44.8% of the 270,740,383 shares outstanding as of July 27, 2026, were present in person or by proxy, satisfying the quorum requirement under the company’s memorandum and articles of association.

Shareholders approved an ordinary resolution to remove Ms. Xin Liu from her position as a director of the company with immediate effect upon passage of the resolution. The resolution received 107,925,508 votes for, 13,313,327 votes against and 55,453 abstentions. The report also states that this information is incorporated by reference into NovaBridge’s effective registration statements on Form F-3 and multiple Form S-8 filings.

NovaBridge Biosciences (NBP) appointed Martin Dewhurst as an independent director to its Board of Directors, effective September 8, 2026, and named him to both the Audit Committee and the Compensation Committee. His background includes more than 30 years of board and C‑suite experience across biotech, biopharma, medical devices, health tech and healthcare investment.

The company highlights his prior leadership roles at McKinsey & Company, including co-leading the Global Life Sciences Practice and co-founding the McKinsey Health Institute, as well as multiple current board and advisory positions in global healthcare organizations. The appointment follows the departure of independent director Liu Xin. This report, excluding the press release exhibit, is incorporated by reference into NovaBridge’s existing Form F‑3 and multiple Form S‑8 registration statements.

NovaBridge Biosciences (NBP) executive Xu Cong Claire, EVP Clinical Development, reported a set of related equity transactions. On August 30, 2026, 4,079 restricted share units were exercised into 9,382 Ordinary Shares, increasing direct holdings of Ordinary Shares to 28,558. On August 31, 2026, she then sold 3,282 Ordinary Shares in a sale in the open market or a private transaction at $0.79 per share, with the reported sales price corresponding to an ADS price of $1.8186.

NovaBridge Biosciences (NBP) director Lenz Robert A. reported an exercise of equity awards and a related share acquisition. On August 22, 2026, he exercised 7,486 restricted share units (RSUs), each convertible into one American Depositary Share (ADS), which together correspond to 17,218 Ordinary Shares. These exercises reduced his RSU balance but increased his direct non-derivative holdings to 17,218 Ordinary Shares, while he continues to hold 14,974 RSUs that remain outstanding and subject to vesting from an original grant of 22,460 RSUs awarded on August 22, 2025.

NovaBridge Biosciences (NBP) reported sharply higher operating expenses and losses for the six months ended June 30, 2026 while advancing its oncology and ophthalmology pipeline. Research and development expenses rose to $14.3 million from $4.1 million, driven mainly by clinical spending on lead Claudin 18.2 bispecific antibody givastomig and broader development capabilities. Administrative expenses increased to $26.4 million from $8.3 million, reflecting higher share-based compensation, headcount growth, and a $3.8 million write-off of deferred costs for a previously proposed Hong Kong dual listing.

Net loss widened to $37.9 million (basic and diluted loss per share $0.14) compared with $8.7 million ($0.05 per share) a year earlier. Cash, cash equivalents, short-term investments and equity investments totaled $215.9 million as of June 30, 2026, which the company believes can fund operations through multiple milestones, including a planned Phase 3 interim read-out for givastomig in 2028. Givastomig received FDA Fast Track Designation for first-line HER2-negative advanced or metastatic gastroesophageal adenocarcinoma and is in a global Phase 2 trial, with a potential registrational Phase 3 start as early as year-end 2026. Ophthalmology asset VIS-101 showed positive Phase 2a data in neovascular AMD and is expected to enter Phase 2b in the second half of 2026.

NovaBridge Biosciences (NBP) furnished an investor presentation outlining its strategy as a global biotechnology platform focused on sourcing differentiated assets and advancing them through disciplined development, financing, and partnering. The lead oncology asset, givastomig, a CLDN18.2 x 4‑1BB bispecific antibody for first-line gastroesophageal adenocarcinoma, has Phase 1b data showing a 77% confirmed overall response rate at 8 mg/kg, disease control rates of 96–100%, median duration of response >15 months, median progression‑free survival of 16.9 months, and 12‑month overall survival of 69%, with FDA Fast Track designation and Accelerated Approval Eligibility and a planned Phase 3 start as early as year-end 2026.

In ophthalmology, VIS‑101, a dual-targeting VEGF‑A/ANG‑2 peptibody for neovascular AMD, DME and RVO, is expected to enter Phase 2b in the second half of 2026, with Phase 3 initiation targeted for 2027 and a projected annual market of about $8 billion; management cites a >90% probability of technical success and China rights sublicensed to Everest Medicines to help fund development. As of June 30, 2026, NovaBridge reports approximately $191 million in cash and cash equivalents and about $25 million in investments at fair value, for roughly $216 million in total, with no debt, which it expects will fund key clinical and strategic milestones through at least the planned 2028 Phase 3 interim analysis for givastomig and multiple readouts for VIS‑101 and partnered assets.